Two cell cycle blocks caused by iron chelation of neuroblastoma cells: Separating cell cycle events associated with each block

Physiological Reports

Volumn 1, Issue 7, 2013, Pages

  Siriwardana, Gamini ^a   Seligman, Paul A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; Iron chelation; Neuroblastoma

Indexed keywords

APHIDICOLIN; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN E; DEFEROXAMINE; HYDROXYUREA;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL GROWTH; CELL MIGRATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IRON CHELATION; NEUROBLASTOMA; WESTERN BLOTTING;

EID: 85008967259     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.176     Document Type: Article

References (45)

1. Blatt, J., and S. Stitely. 1987. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res. 47:1749-1750.
2. Blatt, J., S. R. Taylor, and S. Stitely. 1988. Mechanism of antineuroblastoma activity of deferoxamine in vitro. J. Lab. Clin. Med. 112:433-436.
3. Brodie, C., G. Siriwardana, J. Lucas, R. Schleicher, N. Terada, A. Szepesi, et al. 1993. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 53:3968-3975.
4. Carosio, R., G. Zuccari, I. Orienti, S. Mangraviti, and P. G. Montaldo. 2007. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol. Cancer 6:55.
5. Chaston, T. B., D. B. Lovejoy, R. N. Watts, and D. R. Richardson. 2003. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 9:402-414.
6. Choi, J. G., J. L. Kim, J. Park, S. Lee, S. J. Park, J. S. Kim, et al. 2012. Effects of oral iron chelator deferasirox on human malignant lymphoma cells. Korean J. Hematol. 47:194-201.
7. Donfrancesco, A., G. Deb, C. Dominici, A. Angioni, M. Caniglia, L. De Sio, et al. 1992. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECaT): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol. 15:319-322.
8. Eriksson, S., A. Gräslund, S. Skog, L. Thelander, and B. Tribukait. 1984. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. J. Biol. Chem. 259:11695-11700.
9. Fischer, P. M. 2001. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Discov. Devel. 4:623-634.
10. Ford, S. J., P. Obeidy, D. B. Lovejoy, M. Bedford, L. Nichols, C. Chadwick, et al. 2013. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br. J. Pharmacol. 168:1316-1328.
11. Fu, D., and D. R. Richardson. 2007. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752-761.
12. Greene, B. T., J. Thorburn, M. C. Willingham, A. Thorburn, R. P. Planalp, M. W. Brechbiel, et al. 2002. Activation of caspase pathways during iron chelator-mediated apoptosis. J. Biol. Chem. 277:25568-25575.
13. Helson, C., and L. Helson. 1992. Deferoxamine and human neuroblastoma and primitive neuroectodermal tumor cell lines. Anticancer Res. 12:481-483.
14. Hengst, L., and S. I. Reed. 1996. Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864.
15. Hengst, L., U. Gopfert, H. A. Lashuel, and S. I. Reed. 1998. Complete inhibition of CDK/cyclin by one molecule of p21 (Cip1). Genes Dev. 12:3882-3888.
16. Hoyes, K. P., R. C. Hider, and J. B. Porter. 1992. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res. 52:4591-4599.
17. Huang, S., Z. Zhu, Y. Wang, Y. Wang, L. Xu, X. Chen, et al. 2013. Tet1 is required for RB phosphorylation during G1/S phase transition. Biochem. Biophys. Res. Commun. 434:241-244.
18. Hussain, M. A., N. Green, D. M. Flynn, and A. V. Hoffbrand. 1977. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet 1:977-979.
19. Kastan, M. B., and J. Bartek. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
20. Koc, A., L. J. Wheeler, C. K. Mathews, and G. F. Merrill. 2004. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J. Biol. Chem. 279:223-230.
21. Kontoghiorghes, G. J., A. Piga, and A. V. Hoffbrand. 1986. Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines. Hematol. Oncol. 4:195-204.
22. Krokan, H., E. Wist, and R. H. Krokan. 1981. Aphidicolin inhibits DNA synthesis by DNA polymerase alpha and isolated nuclei by a similar mechanism. Nucleic Acids Res. 9:4709-4719.
23. Lederman, H. M., A. Cohen, J. W. Lee, M. H. Freedman, and E. W. Gelfand. 1984. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64:748-753.
24. Lees, E., B. Faha, V. Dulic, S. Reed, and E. Harlow. 1992. Cyclin E/CDK2 and cyclin A/CDK2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6:1874-1885.
25. Lenarduzzi, M., A. B. Hui, S. Yue, E. Ito, W. Shi, J. Williams, et al. 2013. Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. PLoS One 8:e74075.
26. Lui, G. Y. L., P. Obeidy, S. J. Ford, C. Tselepis, D. M. Sharp, P. J. Jansson, et al. 2013. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharm. 83:179-190.
27. MeSH Browser. 2011. Meta-analysis [about 3 p.]. National Library of Medicine (US), Bethesda, MD. Available at http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?mode=&term=Cyclin+A (Accessed 20 June 1997); MeSH Unique ID: D019925.
28. Nghia, T. V., and D. R. Richardson. 2002. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochem. Biophys. Acta 1603:31-46.
29. Nurtjahja-Tjendraputra, E., D. Fu, J. M. Phang, and D. R. Richardson. 2007. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 109:4045-4054.
30. Philip, T. 1992. Overview of current treatment of neuroblastoma. Am. J. Pediatr. Hematol. Oncol. 14:97-102.
31. Robbins, E., and T. Pederson. 1970. Iron: its intracellular localization and possible role in cell division. Proc. Natl. Acad. Sci. USA 66:1244-1251.
32. Rudland, P. S., H. Durbin, D. Clingan, and L. J. de Asua. 1977. Iron salts and transferrin are specifically required for cell division of cultured 3T6 cells. Biochem. Biophys. Res. Commun. 75:556-562.
33. Seguin, A., D. M. Ward, and J. Kaplan. 2011. Regulation of ribonucleotide reductase during iron limitation. Mol. Cell 44:683-684.
34. Seligman, P. A., and E. D. Crawford. 1991. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J. Natl. Cancer Inst. 83:1582-1584.
35. Seligman, P. A., P. L. Moran, R. B. Schleicher, and E. D. Crawford. 1992. Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am. J. Hematol. 41:232-240.
36. Sheaff, R., D. Ilsley, and R. Kuchta. 1991. Mechanism of DNA polymerase alpha inhibition by aphidicolin. Biochemistry 30:8590-8597.
37. Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73:1059-1065.
38. Siriwardana, G., A. Bradford, D. Coy, and P. Zeitler. 2006. Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol. Endocrinol. 20:2010-2019.
39. Telford, W. G., L. E. King, and P. J. Fraker. 1992. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 13:137-143.
40. Tyrsted, G. 1982. Effect of hydroxyurea and 5-fluorodeoxyuridine on deoxyribonucleoside triphosphate pools early in phytohemagglutinin-stimulated human lymphocytes. Biochem. Pharmacol. 31:3107-3113.
41. Yarbro, J. W. 1992. Mechanism of action of hydroxyurea. Semin. Oncol. 19:1-10.
42. Ye, X., Y. Wei, G. Nalepa, and J. W. Harper. 2003. The cyclin E/CDK2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol. Cell. Biol. 23:8586-8600.
43. Yu, Y., E. Gutierrez, Z. Kovacevic, F. Saletta, P. Obeidy, Y. Suryo Rahmanto, et al. 2012. Iron chelators for the treatment of cancer. Curr. Med. Chem. 19:1689-2702.
44. Zacharski, L. R., B. K. Chow, P. S. Howes, G. Samayeva, J. A. Baron, R. L. Dalman, et al. 2008. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J. Natl. Cancer Inst. 100:996-1002.
45. Zhang, Y., L. Liu, X. Wu, X. An, J. Stubbe, and M. Huang. 2011. Investigation of in vivo diferric tyrosyl radical formation in Saccharomyces cerevisiae Rnr2 protein: requirement of Rnr4 and contribution of Grx3/4 AND Dre2 proteins. J. Biol. Chem. 286:41499-41509.